Middle East and Africa Animal and Human Vaccines Market, By Type (Human and Animal), End User (Hospitals, Clinics, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others) - Industry Trends and Forecast to 2031.
Middle East and Africa Animal and Human Vaccines Market Analysis and Insights
The prevalence of infectious diseases is increasing worldwide and this has been seen that flu and bacterial infectious diseases are surging at a rapid rate, which is boosting the market growth. The mild side-effects which are redness, soreness, or swelling at the injection site can include allergic reactions, and responses are extremely uncommon and it is expected to challenge the market growth.
Data Bridge Market Research analyses that the Middle East and Africa animal and human vaccines market is expected to reach USD 5,358,452.80 thousand by 2031 from USD 3,480,103.50 thousand in 2023, growing with a CAGR of 5.6% in the forecast period of 2024 to 2031.
|
Report Metric |
Details |
|
Forecast Period |
2024 to 2031 |
|
Base Year |
2023 |
|
Historic Years |
2022 (Customizable to 2016-2021) |
|
Quantitative Units |
Revenue in USD Thousand |
|
Segments Covered |
Type (Human and Animal), End User (Hospitals, Clinics, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others) |
|
Countries Covered |
Saudi Arabia, Egypt, U.A.E., Israel, Iran, Iraq, Oman, Kuwait, Qatar, Bahrain, Yemen, Jordan, Lebanon, Palestine, Rest of Middle East, South Africa, Nigeria, Ethiopia, Tanzania, Kenya, Algeria, Ghana, Mozambique, Uganda, Democratic Republic of Congo, Sudan, Morocco, Angola, Madagascar, Malawi, Zambia, Ivory Coast, Cameroon, Zimbabwe, Libya, Chad, Botswana, Namibia, Lesotho, Mauritius, Eswatini, Comoros, Seychelles, and Rest of Africa |
|
Market Players Covered |
GSK plc., Merck & Co., Inc., Sanofi, Boehringer Ingelheim International GmbH., Ceva, ONDERSTEPOORT BIOLOGICAL PRODUCTS SOC (PTY) LTD, M.C.I Santé Animale, Biogénesis Bagó, and HESTER BIOSCIENCES LIMITED among others |
Market Definition
Vaccines are the product that stimulates the individual immune system to induce immunity against a particular disease. Vaccines work on the principle of memory and recognition. When weakened or killed microbes are injected into a body, these microbes cause B cells which are memory cells of the immune system to recognize the pathogen, and in the future, if the same pathogen attacks the body, it works against those. Vaccines have been discovered for several kinds of infectious diseases prevailing around including pneumococcal disease, measles, mumps, rubella, hepatitis, influenza, typhoid, varicella, and rabies among others.
Middle East and Africa Animal and Human Vaccines Market Dynamics
This section deals with understanding the market drivers, opportunities, challenges, and restraints. All of this is discussed in detail below:
Drivers
- Growing Immunization Programs and Campaigns
Implementing a robust immunization program in Middle Eastern and African countries is vital for enhancing public health and preventing the spread of infectious diseases. To ensure the success of such initiatives, it is crucial to undertake comprehensive awareness campaigns. Immunization programs and campaigns are increasing worldwide because of the increasing number of chronic diseases. There is an urgent need to increase awareness regarding vaccination that can be achieved by launching several campaigns and programs, as hepatitis, diphtheria, pertussis, and polio, among other infectious diseases, are prevailing in the environment. This has been reported that the number of immunization programs is increasing with an increase in infectious diseases. Along with this, immunization coverage is also increasing worldwide intending to fight against debilitating diseases.
- Growing Prevalence of Chronic Conditions
The prevalence of infectious diseases is increasing worldwide and this has been seen that flu and bacterial infectious diseases are surging at a rapid rate. This increasing rate of infectious diseases has created the need for disease prevention which can be prevented by vaccination or immunization. There is an urgent need for mass vaccination, as diseases are increasing at a significant rate. Mass vaccinations require a large amount of vaccine disease, hence expected to provide the market with lucrative growth. The prevalence of growing chronic diseases worldwide has significantly heightened the demand for vaccines, thereby expanding the vaccine market. In response to this escalating health challenge, there is a growing recognition of the preventive role that vaccines can play in reducing the incidence and severity of various chronic illnesses.
Opportunity
- Strategic Initiation and Decision taken by the Market Players
Various strategic initiatives are adopted by market players in the vaccine market which involve expansion, collaboration, and acquisition among others. These initiatives allow them to increase the company's product portfolio leading to market expansion and hence enhancing the product demand among customers which ultimately allows the market players to earn maximum revenue. One critical aspect involves continuous investment in research and development to innovate and introduce new vaccines that address emerging health threats. Collaborations with research institutions, government agencies, and Middle East and Africa health organizations help in leveraging collective expertise and resources.
These strategic initiatives are taken by top market players aimed at enhancing business operations and earning more profitability in the market as the demand for effective and novel vaccines is increasing worldwide.
Restraints/Challenges
- Unavailability of Registered Vaccines in the Market
The strict regulatory approvals and time-consuming development procedures for the vaccines are some of the factors that are responsible for the unavailability of registered vaccines. The unavailability of a registered vaccine can have significant implications for public health, creating challenges in disease prevention and control. When a vaccine is not available, it may lead to increased vulnerability to infectious diseases, potential outbreaks, and a higher risk of severe health consequences for the population. Addressing the unavailability of a registered vaccine involves a combination of efforts from regulatory bodies, pharmaceutical companies, and healthcare systems. The regulatory authorities find difficulties in the assessment, licensure, control, and surveillance of vaccines. The world supply of vaccines is delayed due to these regulations.
- Harmful Side Effects Caused by Vaccination
The vaccine is a medical product and helps in preventing different diseases. But sometimes the side-effects arise due to the use of the vaccines. Some of them are the mild side-effects which are redness, soreness, or swelling at the injection site. The vast majority of vaccine side effects are mild and temporary, and the benefits of vaccination in preventing serious illnesses far outweigh the risks. These can include allergic reactions, though severe allergic responses are extremely uncommon. In addition, vaccines, such as any medical intervention, can have rare but serious side effects such as Guillain-Barre Syndrome (GBS) or thrombosis. However, the adverse side effects of the vaccines are rare but are life-threatening.
Recent Developments
- In January 2023, Senvelgo, the recent innovation from Boehringer Ingelheim, has secured the prestigious Animal Health Best New Product for Companion Animals award. This accolade recognizes Senvelgo for its remarkable contribution to simplifying and enhancing the treatment of diabetic cats. Boehringer Ingelheim's commitment to innovation is evident in Senvelgo, offering a solution that is not only simple and safe but also highly convenient for both feline patients and their caregivers
- In 2023, Merck & Co., Inc. received approval from the U.S. Food and Drug Administration (FDA) for KEYTRUDA, its anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for treating patients with FIGO 2014 Stage III-IVA cervical cancer. This approval is based on positive results from the Phase 3 KEYNOTE-A18 trial, where KEYTRUDA combined with CRT showed a 41% reduction in the risk of disease progression or death compared to a placebo plus CRT. The median progression-free survival (PFS) was not reached in either group. This marks the third indication for KEYTRUDA in cervical cancer, emphasizing its effectiveness, and it is the 39th overall indication for KEYTRUDA in the United States. This milestone underscores Merck's commitment to advancing treatment options for patients with various types of cancer
- In July 2023, Biogenesis Bago announced BIOAFTOGEN under the Food and Agriculture Organization of the United Nations (FAO). This marks a historic moment as BIOAFTOGEN becomes the first FMD vaccine to receive such prequalification. This achievement enhances the company´s position as a global leader in FMD prevention and reinforces its commitment to collaboration with leading technical and scientific organizations, contributing to food safety and animal health status worldwide
- In November 2020, GSK plc. along with Medicines for Malaria Venture presented positive data (TEACH study) of tafenoquine used for the treatment of Plasmodium vivax malaria in children and adolescents. During the four months of examination, 95% of study’s 60 subjects did not show signs of Plasmodium vivax malaria. The results were presented through a virtual annual meeting of the American Society of Tropical Medicine & hygiene 2020. This has helped the company to move forward on the product for the treatment of malaria and to provide evidence of their product
- In November 2020, Sanofi received approval from the European Commission for Supemtek (quadrivalent recombinant influenza vaccine) for the prevention of influenza disease in adults aged 18 years or older. This approval helped the company to advance its product portfolio involving vaccines and to strengthen its roots in the European vaccine market
Middle East and Africa Animal and Human Vaccines Market Scope
The Middle East and Africa animal and human vaccines market is categorized into three notable segments based on type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Human
- Animal
On the basis of type, the Middle East and Africa animal and human vaccines market is segmented into human and animal.
End User
- Hospitals
- Clinics
- Others
On the basis of end user, the Middle East and Africa animal and human vaccines market is segmented into hospitals, clinics, and others.
Distribution Channel
- Direct Tenders
- Retail Sales
- Others
On the basis of distrution channel, the Middle East and Africa animal and human vaccines market is segmented into direct tender, retail sales, and others.
Middle East and Africa Animal and Human Vaccines Market Regional Analysis/Insights
The Middle East and Africa animal and vaccines market is categorized into three notable segments into type, end user, and distribution channel.
The countries covered in this market report are Saudi Arabia, Egypt, U.A.E., Israel, Iran, Iraq, Oman, Kuwait, Qatar, Bahrain, Yemen, Jordan, Lebanon, Palestine, rest of Middle East, South Africa, Nigeria, Ethiopia, Tanzania, Kenya, Algeria, Ghana, Mozambique, Uganda, Democratic Republic of Congo, Sudan, Morocco, Angola, Madagascar, Malawi, Zambia, Ivory Coast, Cameroon, Zimbabwe, Libya, Chad, Botswana, Namibia, Lesotho, Mauritius, Eswatini, Comoros, Seychelles, and rest of Africa.
South Africa is expected to dominate the Africa animal and vaccines market due to increasing government support and funding in the country. Saudi Arabia is expected to dominate the Middle East animal and vaccines market due to growing immunization programs and campaigns.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Middle East and Africa Animal and Human Vaccines Market Competitive Landscape and Share Analysis
Middle East and Africa animal and human vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, product type lifeline curve. The above data points provided are only related to the company’s focus on the Middle East and Africa animal and human vaccines market.
Some of the major players operating in the Middle East and Africa animal and human vaccines market are GSK plc., Merck & Co., Inc., Sanofi, Boehringer Ingelheim International GmbH., Ceva, ONDERSTEPOORT BIOLOGICAL PRODUCTS SOC (PTY) LTD, M.C.I Santé Animale, Biogénesis Bagó, and HESTER BIOSCIENCES LIMITED among others.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 REGULATORY SCENARIO
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS
6.1.2 GROWING PREVALENCE OF CHRONIC CONDITIONS
6.1.3 PRODUCTION OF NEW VACCINES IN THE HEALTHCARE MARKET
6.1.4 INCREASING GOVERNMENT SUPPORT AND FUNDING
6.2 RESTRAINTS
6.2.1 UNAVAILABILITY OF REGISTERED VACCINES IN THE MARKET
6.2.2 HIGH COST AND DIFFERENCES IN PRICING OF THE VACCINES
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATION AND DECISION TAKEN BY THE MARKET PLAYERS
6.3.2 RISING PREVALENCE OF PIPELINE PRODUCTS
6.3.3 EMPHASIZING THE ROLE OF VACCINATION IN INDIVIDUAL AND COMMUNITY
6.4 CHALLENGES
6.4.1 HARMFUL SIDE EFFECTS CAUSED BY VACCINATION
6.4.2 FEAR AMONG PATIENTS RELATED TO INJECTIONS AND NEEDLE STICKS
7 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY TYPE
7.1 OVERVIEW
7.2 HUMAN
7.2.1 HUMAN PAPILLOMAVIRUS (HPV)
7.2.1.1 CERVICAL CANCER
7.2.1.2 OROPHARYNGEAL CANCER
7.2.1.3 ANAL CANCER
7.2.1.4 VULVAR AND VAGINAL CANCER
7.2.1.5 PENILE CANCER
7.2.1.6 OTHERS
7.2.2 PNEUMOCOCCAL VACCINE (PCV)
7.2.3 DTAP VACCINE
7.2.4 ROTAVIRUS VACCINE
7.2.5 INFLUENZA VACCINE
7.2.6 OTHERS
7.3 ANIMAL
7.3.1 BRUCELLOSIS
7.3.1.1 LIVE
7.3.1.2 INACTIVATED
7.3.1.2.1 CATTLE
7.3.1.2.2 CAPRINE
7.3.1.2.3 OVINE
7.3.2 FOOT AND MOUTH
7.3.2.1 INACTIVATED
7.3.2.2 LIVE
7.3.2.2.1 CATTLE
7.3.2.2.2 SHEEP AND GOAT
7.3.2.2.3 PIGS
7.3.2.2.4 OTHERS
7.3.3 AFRICAN HORSE SICKNESS
7.3.3.1 LIVE
7.3.3.2 INACTIVATED
7.3.3.2.1 HORSE
7.3.3.2.2 DONKEY
7.3.3.2.3 MULES
7.3.4 RIFT VALLEY FEVER
7.3.4.1 LIVE
7.3.4.2 INACTIVATED
7.3.4.2.1 SMITHBURN STRAIN BASED VACCINE
7.3.4.2.2 ALUMINUM HYDROXIDE GEL AS ADJUVANT BASED VACCINE
7.3.4.2.3 Others
8 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITAL
8.2.1 HUMAN HOSPITALS
8.2.2 VETERINARY HOSPITALS
8.3 CLINICS
8.3.1 SPECIALTY CLINICS
8.3.2 VETERINARY CLINICS
8.4 OTHERS
8.4.1 ANIMAL HUSBANDRY
8.4.2 PET SHOPS
8.4.3 OTHERS
9 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 DIRECT TENDERS
9.3 RETAIL SALES
9.4 OTHERS
10 MIDDLE EAST & AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY COUNTRY
10.1 MIDDLE EAST & AFRICA
10.2 MIDDLE EAST
10.2.1 SAUDI ARABIA
10.2.2 EGYPT
10.2.3 U.A.E.
10.2.4 ISRAEL
10.2.5 IRAN
10.2.6 IRAQ
10.2.7 OMAN
10.2.8 KUWAIT
10.2.9 QATAR
10.2.10 BAHRAIN
10.2.11 YEMEN
10.2.12 JORDAN
10.2.13 LEBANON
10.2.14 PALESTINE
10.2.15 REST OF MIDDLE EAST
10.3 AFRICA
10.3.1 SOUTH AFRICA
10.3.2 NIGERIA
10.3.3 ETHIOPIA
10.3.4 TANZANIA
10.3.5 KENYA
10.3.6 ALGERIA
10.3.7 GHANA
10.3.8 MOZAMBIQUE
10.3.9 UGANDA
10.3.10 DEMOCRATIC REPUBLIC OF CONGO
10.3.11 SUDAN
10.3.12 MOROCCO
10.3.13 ANGOLA
10.3.14 MADAGASCAR
10.3.15 MALAWI
10.3.16 ZAMBIA
10.3.17 IVORY COAST
10.3.18 CAMEROON
10.3.19 ZIMBABWE
10.3.20 LIBYA
10.3.21 CHAD
10.3.22 BOTSWANA
10.3.23 NAMIBIA
10.3.24 LESOTHO
10.3.25 MAURITIUS
10.3.26 ESWATINI
10.3.27 COMOROS
10.3.28 SEYCHELLES
10.3.29 REST OF AFRICA
11 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
12 SWOT ANALYSIS
13 COMPANY PROFILES
13.1 GSK PLC.
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 PRODUCT PORTFOLIO
13.1.4 RECENT DEVELOPMENTS
13.2 MERCK & CO., INC.
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENTS
13.3 SANOFI
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 PRODUCT PORTFOLIO
13.3.4 RECENT DEVELOPMENTS
13.4 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.4.1 COMPANY SNAPSHOT
13.4.2 PRODUCT PORTFOLIO
13.4.3 RECENT DEVELOPMENT
13.5 CEVA SANTÉ ANIMALE
13.5.1 COMPANY SNAPSHOT
13.5.2 PRODUCT PORTFOLIO
13.5.3 RECENT DEVELOPMENT
13.6 BIOGENESIS BAGO SA
13.6.1 COMPANY SNAPSHOT
13.6.2 PRODUCT PORTFOLIO
13.6.3 RECENT DEVELOPMENT
13.7 HESTER BIOSCIENCES LTD
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENT
13.8 M.C.I. SANTÉ ANIMALE
13.8.1 COMPANY SNAPSHOT
13.8.2 PRODUCT PORTFOLIO
13.8.3 RECENT DEVELOPMENT
13.9 ONDERSTEPOORT BIOLOGICAL PRODUCTS SOC (PYT) LTD
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENTS
14 QUESTIONNAIRE
15 RELATED REPORTS
Lista de Tablas
TABLE 1 VACCINES UNDER CLINICAL TRIAL
TABLE 2 THE SIDE EFFECTS RELATED TO VACCINES
TABLE 3 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY TYPE 2022-2031 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 6 MIDDLE EAST AND AFRICA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
THE AFRICAN HORSE SICKNESS SEGMENT IS FURTHER SUB-SEGMENTED BY TYPE INTO LIVE AND INACTIVATED. 92
TABLE 11 MIDDLE EAST AND AFRICA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 20 MIDDLE EAST ANIMAL AND HUMAN VACCINES MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 21 MIDDLE EAST ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 22 MIDDLE EAST HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 23 MIDDLE EAST HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 24 MIDDLE EAST ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 25 MIDDLE EAST BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 26 MIDDLE EAST BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 27 MIDDLE EAST FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 28 MIDDLE EAST FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 29 MIDDLE EAST AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 30 MIDDLE EAST AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 31 MIDDLE EAST RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 32 MIDDLE EAST RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 33 MIDDLE EAST ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 34 MIDDLE EAST HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 35 MIDDLE EAST CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 36 MIDDLE EAST OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 37 MIDDLE EAST ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 38 SAUDI ARABIA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 39 SAUDI ARABIA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 40 SAUDI ARABIA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 41 SAUDI ARABIA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 42 SAUDI ARABIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 43 SAUDI ARABIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 44 SAUDI ARABIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 45 SAUDI ARABIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 46 SAUDI ARABIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 47 SAUDI ARABIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 48 SAUDI ARABIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 49 SAUDI ARABIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 50 SAUDI ARABIA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 51 SAUDI ARABIA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 52 SAUDI ARABIA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 53 SAUDI ARABIA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 SAUDI ARABIA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 55 EGYPT ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 56 EGYPT HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 57 EGYPT HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 58 EGYPT ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 59 EGYPT BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 60 EGYPT BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 61 EGYPT FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 62 EGYPT FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 63 EGYPT AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 64 EGYPT AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 65 EGYPT RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 66 EGYPT RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 67 EGYPT ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 68 EGYPT HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 EGYPT CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 EGYPT OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 71 EGYPT ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 72 U.A.E. ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 73 U.A.E. HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 74 U.A.E. HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 75 U.A.E. ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 U.A.E. BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 77 U.A.E. BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 78 U.A.E. FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 U.A.E. FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 80 U.A.E. AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 81 U.A.E. AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 82 U.A.E. RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 83 U.A.E. RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 84 U.A.E. ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 85 U.A.E. HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 86 U.A.E. CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 87 U.A.E. OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 88 U.A.E. ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 89 ISRAEL ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 ISRAEL HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 91 ISRAEL HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 92 ISRAEL ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 ISRAEL BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 94 ISRAEL BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 95 ISRAEL FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 ISRAEL FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 97 ISRAEL AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 98 ISRAEL AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 99 ISRAEL RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 100 ISRAEL RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 101 ISRAEL ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 102 ISRAEL HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 103 ISRAEL CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 104 ISRAEL OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 105 ISRAEL ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 106 IRAN ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 107 IRAN HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 108 IRAN HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 109 IRAN ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 110 IRAN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 111 IRAN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 112 IRAN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 113 IRAN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 114 IRAN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 115 IRAN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 116 IRAN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 IRAN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 118 IRAN ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 119 IRAN HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 120 IRAN CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 121 IRAN OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 122 IRAN ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 123 IRAQ ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 IRAQ HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 125 IRAQ HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 126 IRAQ ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 127 IRAQ BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 128 IRAQ BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 129 IRAQ FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 130 IRAQ FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 131 IRAQ AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 132 IRAQ AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 133 IRAQ RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 134 IRAQ RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 IRAQ ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 136 IRAQ HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 137 IRAQ CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 138 IRAQ OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 139 IRAQ ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 140 OMAN ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 141 OMAN HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 142 OMAN HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 143 OMAN ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 144 OMAN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 145 OMAN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 146 OMAN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 147 OMAN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 148 OMAN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 149 OMAN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 150 OMAN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 151 OMAN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 152 OMAN ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 153 OMAN HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 154 OMAN CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 155 OMAN OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 156 OMAN ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 157 KUWAIT ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 158 KUWAIT HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 159 KUWAIT HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 160 KUWAIT ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 161 KUWAIT BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 162 KUWAIT BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 163 KUWAIT FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 164 KUWAIT FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 165 KUWAIT AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 166 KUWAIT AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 167 KUWAIT RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 168 KUWAIT RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 169 KUWAIT ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 170 KUWAIT HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 171 KUWAIT CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 172 KUWAIT OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 173 KUWAIT ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 174 QATAR ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 175 QATAR HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 176 QATAR HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 177 QATAR ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 178 QATAR BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 179 QATAR BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 180 QATAR FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 181 QATAR FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 182 QATAR AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 183 QATAR AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 184 QATAR RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 185 QATAR RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 186 QATAR ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 187 QATAR HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 188 QATAR CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 189 QATAR OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 190 QATAR ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 191 BAHRAIN ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 192 BAHRAIN HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 193 BAHRAIN HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 194 BAHRAIN ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 195 BAHRAIN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 196 BAHRAIN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 197 BAHRAIN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 198 BAHRAIN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 199 BAHRAIN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 200 BAHRAIN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 201 BAHRAIN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 202 BAHRAIN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 203 BAHRAIN ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 204 BAHRAIN HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 205 BAHRAIN CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 206 BAHRAIN OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 207 BAHRAIN ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 208 YEMEN ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 209 YEMEN HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 210 YEMEN HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 211 YEMEN ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 212 YEMEN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 213 YEMEN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 214 YEMEN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 215 YEMEN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 216 YEMEN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 217 YEMEN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 218 YEMEN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 219 YEMEN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 220 YEMEN ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 221 YEMEN HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 222 YEMEN CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 223 YEMEN OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 224 YEMEN ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 225 JORDAN ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 226 JORDAN HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 227 JORDAN HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 228 JORDAN ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 229 JORDAN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 230 JORDAN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 231 JORDAN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 232 JORDAN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 233 JORDAN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 234 JORDAN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 235 JORDAN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 236 JORDAN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 237 JORDAN ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 238 JORDAN HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 239 JORDAN CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 240 JORDAN OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 241 JORDAN ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 242 LEBANON ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 243 LEBANON HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 244 LEBANON HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 245 LEBANON ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 246 LEBANON BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 247 LEBANON BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 248 LEBANON FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 249 LEBANON FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 250 LEBANON AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 251 LEBANON AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 252 LEBANON RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 253 LEBANON RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 254 LEBANON ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 255 LEBANON HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 256 LEBANON CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 257 LEBANON OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 258 LEBANON ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 259 PALESTINE ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 260 PALESTINE HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 261 PALESTINE HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 262 PALESTINE ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 263 PALESTINE BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 264 PALESTINE BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 265 PALESTINE FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 266 PALESTINE FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 267 PALESTINE AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 268 PALESTINE AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 269 PALESTINE RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 270 PALESTINE RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 271 PALESTINE ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 272 PALESTINE HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 273 PALESTINE CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 274 PALESTINE OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 275 PALESTINE ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 276 REST OF MIDDLE EAST ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 277 AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 278 AFRICA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 279 AFRICA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 280 AFRICA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 281 AFRICA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 282 AFRICA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 283 AFRICA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 284 AFRICA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 285 AFRICA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 286 AFRICA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 287 AFRICA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 288 AFRICA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 289 AFRICA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 290 AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 291 AFRICA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 292 AFRICA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 293 AFRICA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 294 AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 295 SOUTH AFRICA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 296 SOUTH AFRICA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 297 SOUTH AFRICA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 298 SOUTH AFRICA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 299 SOUTH AFRICA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 300 SOUTH AFRICA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 301 SOUTH AFRICA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 302 SOUTH AFRICA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 303 SOUTH AFRICA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 304 SOUTH AFRICA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 305 SOUTH AFRICA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 306 SOUTH AFRICA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 307 SOUTH AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 308 SOUTH AFRICA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 309 SOUTH AFRICA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 310 SOUTH AFRICA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 311 SOUTH AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 312 NIGERIA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 313 NIGERIA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 314 NIGERIA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 315 NIGERIA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 316 NIGERIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 317 NIGERIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 318 NIGERIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 319 NIGERIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 320 NIGERIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 321 NIGERIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 322 NIGERIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 323 NIGERIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 324 NIGERIA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 325 NIGERIA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 326 NIGERIA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 327 NIGERIA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 328 NIGERIA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 329 ETHIOPIA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 330 ETHIOPIA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 331 ETHIOPIA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 332 ETHIOPIA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 333 ETHIOPIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 334 ETHIOPIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 335 ETHIOPIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 336 ETHIOPIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 337 ETHIOPIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 338 ETHIOPIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 339 ETHIOPIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 340 ETHIOPIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 341 ETHIOPIA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 342 ETHIOPIA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 343 ETHIOPIA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 344 ETHIOPIA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 345 ETHIOPIA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 346 TANZANIA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 347 TANZANIA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 348 TANZANIA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 349 TANZANIA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 350 TANZANIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 351 TANZANIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 352 TANZANIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 353 TANZANIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 354 TANZANIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 355 TANZANIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 356 TANZANIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 357 TANZANIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 358 TANZANIA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 359 TANZANIA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 360 TANZANIA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 361 TANZANIA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 362 TANZANIA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 363 KENYA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 364 KENYA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 365 KENYA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 366 KENYA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 367 KENYA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 368 KENYA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 369 KENYA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 370 KENYA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 371 KENYA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 372 KENYA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 373 KENYA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 374 KENYA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 375 KENYA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 376 KENYA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 377 KENYA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 378 KENYA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 379 KENYA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 380 ALGERIA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 381 ALGERIA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 382 ALGERIA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 383 ALGERIA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 384 ALGERIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 385 ALGERIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 386 ALGERIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 387 ALGERIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 388 ALGERIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 389 ALGERIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 390 ALGERIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 391 ALGERIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 392 ALGERIA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 393 ALGERIA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 394 ALGERIA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 395 ALGERIA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 396 ALGERIA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 397 GHANA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 398 GHANA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 399 GHANA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 400 GHANA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 401 GHANA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 402 GHANA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 403 GHANA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 404 GHANA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 405 GHANA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 406 GHANA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 407 GHANA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 408 GHANA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 409 GHANA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 410 GHANA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 411 GHANA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 412 GHANA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 413 GHANA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 414 MOZAMBIQUE ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 415 MOZAMBIQUE HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 416 MOZAMBIQUE HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 417 MOZAMBIQUE ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 418 MOZAMBIQUE BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 419 MOZAMBIQUE BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 420 MOZAMBIQUE FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 421 MOZAMBIQUE FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 422 MOZAMBIQUE AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 423 MOZAMBIQUE AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 424 MOZAMBIQUE RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 425 MOZAMBIQUE RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 426 MOZAMBIQUE ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 427 MOZAMBIQUE HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 428 MOZAMBIQUE CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 429 MOZAMBIQUE OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 430 MOZAMBIQUE ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 431 UGANDA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 432 UGANDA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 433 UGANDA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 434 UGANDA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 435 UGANDA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 436 UGANDA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 437 UGANDA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 438 UGANDA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 439 UGANDA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 440 UGANDA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 441 UGANDA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 442 UGANDA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 443 UGANDA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 444 UGANDA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 445 UGANDA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 446 UGANDA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 447 UGANDA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 448 DEMOCRATIC REPUBLIC OF CONGO ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 449 DEMOCRATIC REPUBLIC OF CONGO HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 450 DEMOCRATIC REPUBLIC OF CONGO HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 451 DEMOCRATIC REPUBLIC OF CONGO ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 452 DEMOCRATIC REPUBLIC OF CONGO BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 453 DEMOCRATIC REPUBLIC OF CONGO BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 454 DEMOCRATIC REPUBLIC OF CONGO FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 455 DEMOCRATIC REPUBLIC OF CONGO FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 456 DEMOCRATIC REPUBLIC OF CONGO AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 457 DEMOCRATIC REPUBLIC OF CONGO AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 458 DEMOCRATIC REPUBLIC OF CONGO RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 459 DEMOCRATIC REPUBLIC OF CONGO RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 460 DEMOCRATIC REPUBLIC OF CONGO ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 461 DEMOCRATIC REPUBLIC OF CONGO HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 462 DEMOCRATIC REPUBLIC OF CONGO CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 463 DEMOCRATIC REPUBLIC OF CONGO OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 464 DEMOCRATIC REPUBLIC OF CONGO ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 465 SUDAN ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 466 SUDAN HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 467 SUDAN HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 468 SUDAN ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 469 SUDAN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 470 SUDAN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 471 SUDAN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 472 SUDAN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 473 SUDAN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 474 SUDAN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 475 SUDAN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 476 SUDAN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 477 SUDAN ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 478 SUDAN HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 479 SUDAN CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 480 SUDAN OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 481 SUDAN ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 482 MOROCCO ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 483 MOROCCO HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 484 MOROCCO HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 485 MOROCCO ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 486 MOROCCO BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 487 MOROCCO BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 488 MOROCCO FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 489 MOROCCO FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 490 MOROCCO AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 491 MOROCCO AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 492 MOROCCO RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 493 MOROCCO RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 494 MOROCCO ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 495 MOROCCO HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 496 MOROCCO CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 497 MOROCCO OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 498 MOROCCO ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 499 ANGOLA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 500 ANGOLA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 501 ANGOLA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 502 ANGOLA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 503 ANGOLA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 504 ANGOLA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 505 ANGOLA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 506 ANGOLA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 507 ANGOLA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 508 ANGOLA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 509 ANGOLA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 510 ANGOLA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 511 ANGOLA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 512 ANGOLA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 513 ANGOLA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 514 ANGOLA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 515 ANGOLA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 516 MADAGASCAR ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 517 MADAGASCAR HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 518 MADAGASCAR HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 519 MADAGASCAR ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 520 MADAGASCAR BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 521 MADAGASCAR BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 522 MADAGASCAR FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 523 MADAGASCAR FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 524 MADAGASCAR AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 525 MADAGASCAR AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 526 MADAGASCAR RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 527 MADAGASCAR RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 528 MADAGASCAR ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 529 MADAGASCAR HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 530 MADAGASCAR CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 531 MADAGASCAR OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 532 MADAGASCAR ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 533 MALAWI ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 534 MALAWI HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 535 MALAWI HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 536 MALAWI ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 537 MALAWI BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 538 MALAWI BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 539 MALAWI FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 540 MALAWI FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 541 MALAWI AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 542 MALAWI AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 543 MALAWI RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 544 MALAWI RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 545 MALAWI ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 546 MALAWI HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 547 MALAWI CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 548 MALAWI OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 549 MALAWI ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 550 ZAMBIA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 551 ZAMBIA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 552 ZAMBIA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 553 ZAMBIA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 554 ZAMBIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 555 ZAMBIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 556 ZAMBIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 557 ZAMBIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 558 ZAMBIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 559 ZAMBIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 560 ZAMBIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 561 ZAMBIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 562 ZAMBIA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 563 ZAMBIA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 564 ZAMBIA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 565 ZAMBIA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 566 ZAMBIA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 567 IVORY COAST ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 568 IVORY COAST HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 569 IVORY COAST HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 570 IVORY COAST ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 571 IVORY COAST BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 572 IVORY COAST BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 573 IVORY COAST FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 574 IVORY COAST FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 575 IVORY COAST AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 576 IVORY COAST AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 577 IVORY COAST RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 578 IVORY COAST RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 579 IVORY COAST ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 580 IVORY COAST HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 581 IVORY COAST CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 582 IVORY COAST OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 583 IVORY COAST ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 584 CAMEROON ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 585 CAMEROON HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 586 CAMEROON HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 587 CAMEROON ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 588 CAMEROON BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 589 CAMEROON BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 590 CAMEROON FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 591 CAMEROON FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 592 CAMEROON AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 593 CAMEROON AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 594 CAMEROON RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 595 CAMEROON RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 596 CAMEROON ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 597 CAMEROON HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 598 CAMEROON CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 599 CAMEROON OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 600 CAMEROON ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 601 ZIMBABWE ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 602 ZIMBABWE HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 603 ZIMBABWE HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 604 ZIMBABWE ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 605 ZIMBABWE BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 606 ZIMBABWE BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 607 ZIMBABWE FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 608 ZIMBABWE FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 609 ZIMBABWE AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 610 ZIMBABWE AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 611 ZIMBABWE RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 612 ZIMBABWE RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 613 ZIMBABWE ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 614 ZIMBABWE HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 615 ZIMBABWE CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 616 ZIMBABWE OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 617 ZIMBABWE ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 618 LIBYA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 619 LIBYA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 620 LIBYA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 621 LIBYA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 622 LIBYA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 623 LIBYA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 624 LIBYA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 625 LIBYA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 626 LIBYA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 627 LIBYA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 628 LIBYA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 629 LIBYA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 630 LIBYA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 631 LIBYA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 632 LIBYA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 633 LIBYA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 634 LIBYA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 635 CHAD ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 636 CHAD HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 637 CHAD HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 638 CHAD ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 639 CHAD BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 640 CHAD BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 641 CHAD FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 642 CHAD FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 643 CHAD AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 644 CHAD AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 645 CHAD RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 646 CHAD RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 647 CHAD ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 648 CHAD HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 649 CHAD CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 650 CHAD OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 651 CHAD ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 652 BOTSWANA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 653 BOTSWANA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 654 BOTSWANA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 655 BOTSWANA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 656 BOTSWANA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 657 BOTSWANA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 658 BOTSWANA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 659 BOTSWANA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 660 BOTSWANA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 661 BOTSWANA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 662 BOTSWANA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 663 BOTSWANA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 664 BOTSWANA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 665 BOTSWANA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 666 BOTSWANA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 667 BOTSWANA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 668 BOTSWANA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 669 NAMIBIA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 670 NAMIBIA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 671 NAMIBIA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 672 NAMIBIA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 673 NAMIBIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 674 NAMIBIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 675 NAMIBIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 676 NAMIBIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 677 NAMIBIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 678 NAMIBIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 679 NAMIBIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 680 NAMIBIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 681 NAMIBIA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 682 NAMIBIA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 683 NAMIBIA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 684 NAMIBIA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 685 NAMIBIA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 686 LESOTHO ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 687 LESOTHO HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 688 LESOTHO HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 689 LESOTHO ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 690 LESOTHO BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 691 LESOTHO BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 692 LESOTHO FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 693 LESOTHO FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 694 LESOTHO AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 695 LESOTHO AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 696 LESOTHO RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 697 LESOTHO RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 698 LESOTHO ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 699 LESOTHO HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 700 LESOTHO CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 701 LESOTHO OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 702 LESOTHO ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 703 MAURITIUS ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 704 MAURITIUS HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 705 MAURITIUS HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 706 MAURITIUS ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 707 MAURITIUS BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 708 MAURITIUS BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 709 MAURITIUS FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 710 MAURITIUS FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 711 MAURITIUS AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 712 MAURITIUS AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 713 MAURITIUS RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 714 MAURITIUS RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 715 MAURITIUS ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 716 MAURITIUS HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 717 MAURITIUS CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 718 MAURITIUS OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 719 MAURITIUS ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 720 ESWATINI ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 721 ESWATINI HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 722 ESWATINI HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 723 ESWATINI ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 724 ESWATINI BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 725 ESWATINI BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 726 ESWATINI FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 727 ESWATINI FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 728 ESWATINI AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 729 ESWATINI AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 730 ESWATINI RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 731 ESWATINI RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 732 ESWATINI ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 733 ESWATINI HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 734 ESWATINI CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 735 ESWATINI OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 736 ESWATINI ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 737 COMOROS ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 738 COMOROS HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 739 COMOROS HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 740 COMOROS ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 741 COMOROS BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 742 COMOROS BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 743 COMOROS FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 744 COMOROS FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 745 COMOROS AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 746 COMOROS AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 747 COMOROS RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 748 COMOROS RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 749 COMOROS ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 750 COMOROS HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 751 COMOROS CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 752 COMOROS OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 753 COMOROS ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 754 SEYCHELLES ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
TABLE 755 SEYCHELLES HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 756 SEYCHELLES HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)
TABLE 757 SEYCHELLES ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 758 SEYCHELLES BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 759 SEYCHELLES BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 760 SEYCHELLES FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 761 SEYCHELLES FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 762 SEYCHELLES AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 763 SEYCHELLES AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)
TABLE 764 SEYCHELLES RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 765 SEYCHELLES RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)
TABLE 766 SEYCHELLES ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 767 SEYCHELLES HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 768 SEYCHELLES CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 769 SEYCHELLES OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 770 SEYCHELLES ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 771 REST OF AFRICA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)
Lista de figuras
FIGURE 1 INDIA AND EUROPE GENERIC INJECTABLES MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: SEGMENTATION
FIGURE 10 ESCALATING INCIDENCE OF CHRONIC DISEASES AND SURGE IN THE DEVELOPMENT AND PRODUCTION OF VACCINES ARE DRIVING THE GROWTH OF THE MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 11 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET IN 2024 AND 2031
FIGURE 12 OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET
FIGURE 13 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY TYPE, 2023
FIGURE 14 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 15 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 16 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY TYPE, LIFELINE CURVE
FIGURE 17 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY END USER, 2023
FIGURE 18 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 19 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY END USER, CAGR (2024-2031)
FIGURE 20 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY END USER, LIFELINE CURVE
FIGURE 21 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 22 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 23 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 24 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 25 MIDDLE EAST &AFRICA ANIMAL AND HUMAN VACCINES MARKET: SNAPSHOT (2023)
FIGURE 26 MIDDLE EAST ANIMAL AND HUMAN VACCINES MARKET: SNAPSHOT (2023)
FIGURE 27 AFRICA ANIMAL AND HUMAN VACCINES MARKET: SNAPSHOT (2023)
FIGURE 28 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: COMPANY SHARE 2023 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
